Comparative Pharmacology
Head-to-head clinical analysis: JENTADUETO versus NESINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JENTADUETO versus NESINA.
JENTADUETO vs NESINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Jentadueto is a combination of linagliptin and metformin. Linagliptin inhibits DPP-4, increasing incretin levels (GLP-1, GIP) and enhancing glucose-dependent insulin secretion while suppressing glucagon. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
Inhibitor of dipeptidyl peptidase-4 (DPP-4), preventing inactivation of incretin hormones (GLP-1, GIP), thereby increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner.
Administered orally twice daily with meals. Initial dose: one tablet JENTADUETO 5 mg/500 mg or 5 mg/1000 mg; subsequent titration based on glycemic response. Maximum daily dose: linagliptin 5 mg, metformin 2000 mg.
25 mg orally once daily.
None Documented
None Documented
Linagliptin: terminal t1/2 ~12 hours (long binding to DPP-4). Metformin: terminal t1/2 ~6.2 hours (renal impairment prolongs).
Terminal elimination half-life: 12.4–26.1 hours (mean ~21 hours); supports once-daily dosing
Renal: linagliptin ~5% unchanged; metformin ~90% unchanged. Fecal: linagliptin ~80% (mostly unchanged). Biliary: minimal.
Renal: 87% (75% as unchanged drug, 12% as inactive metabolites); Fecal: <1%
Category C
Category C
DPP-4 Inhibitor / Biguanide Combination
DPP-4 Inhibitor